Simcere Pharmaceutical Group Limited (2096) Financial History

Name: Simcere Pharmaceutical Group Limited (2096) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-11

Simcere Pharmaceutical Group Limited (2096) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Nanjing, China with about 7,038 employees. Its market capitalization is roughly CNY 32 billion. In the fiscal year ended 2025-12-31, 2096 reported CNY 7.7B in revenue and CNY 1.3B in net income.

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.

Interactive charts & full statements →

2096 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	CNY 7.7B	CNY 6.6B	CNY 6.6B	CNY 6.3B	—
Gross Profit	CNY 6.3B	CNY 5.3B	CNY 5.0B	CNY 5.0B	—
Operating Income (EBIT)	CNY 1.4B	CNY 1.1B	CNY 700M	CNY 545M	—
Net Income	CNY 1.3B	CNY 722M	CNY 715M	CNY 931M	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2096 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	(CNY 391M)	(CNY 402M)	(CNY 419M)	(CNY 391M)	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2096 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CNY 14.7B	CNY 11.6B	CNY 10.9B	CNY 10.8B	—
Total Liabilities	CNY 5.3B	CNY 4.5B	CNY 3.6B	CNY 3.6B	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2096 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

GALD · GALDERMA GROUP N — $40 billion
4577 · Daito Pharmaceutical Co.,Ltd. — $37 billion
4595 · Mizuho Medy Co.,Ltd. — $33 billion
9273 · Koa Shoji Holdings Co.,Ltd. — $32 billion
SDZ · Sandoz Group AG — $32 billion
HLN · Haleon plc — $31 billion
3320 · China Resources Pharmaceutical Group Limited — $30 billion
0867 · China Medical System Holdings Limited — $30 billion

← 2088 All “0-9” companies 2097 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.